1. Classification:

• Type: Janus Kinase (JAK) Inhibitor
• Class: Antineoplastic Agent

2. Indications:

• Jakavi, with the active ingredient ruxolitinib, is primarily used for the treatment of certain myeloproliferative neoplasms, including:
  • Intermediate or high-risk myelofibrosis (MF)
  • Polycythemia vera (PV) in individuals who are resistant or intolerant to hydroxyurea
  • Acute graft-versus-host disease (GVHD) in individuals after allogeneic hematopoietic stem cell transplantation.

3. Mechanism of Action:

• Ruxolitinib is a JAK inhibitor that interferes with the signaling pathways associated with Janus kinases. By inhibiting these pathways, Jakavi helps regulate the abnormal cellular proliferation observed in certain myeloproliferative neoplasms.

4. Administration:

• Jakavi is typically administered orally in the form of tablets. The dosage and treatment plan are determined by the healthcare provider based on the specific condition being treated and the patient’s individual response.

5. Dosage Forms:

• The description mentions “Ruxolitinib 5 mg Tablets 56’S,” indicating that the tablets contain 5 mg of ruxolitinib, and the package includes 56 tablets.

6. Dosage and Treatment Plan:

• The dosage and treatment plan with Jakavi depend on the type and severity of the myeloproliferative neoplasm being treated. It is important for patients to follow the prescribed dosage and schedule.

7. Side Effects:

• Common side effects of Jakavi may include anemia, thrombocytopenia, bruising, dizziness, and increased cholesterol levels. As with any medication, patients are advised to report any unusual or severe side effects to their healthcare provider.

8. Precautions:

• Jakavi should be used with caution in patients with certain pre-existing conditions. Regular monitoring of blood counts, liver function, and cholesterol levels is often recommended during treatment.

9. Consultation with a Healthcare Provider:

• Before starting Jakavi treatment, patients should have a comprehensive consultation with their healthcare provider. The healthcare team will assess the patient’s overall health, medical history, and the specific characteristics of the myeloproliferative neoplasm being treated.

10. Pregnancy and Contraindications:

• Jakavi may cause harm to a developing fetus, and it is generally contraindicated during pregnancy. Women of childbearing potential should use effective contraception during Jakavi treatment.

Patients should always consult with their healthcare provider for personalized advice, including information on dosage, side effects, and potential interactions. The details provided here are general in nature, and the specific prescribing information may vary based on the region and formulation.